Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 20;7(16):4013–4028. doi: 10.7150/thno.19304

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Ivyspring International Publisher

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Integrin α2 (ITGA2) expression was up-regulated in NSCLC in clinical cancer samples in ten datasets from the Oncomine online microarray database. The mRNA level of integrin α2 (ITGA2) in clinical NSCLC tumor tissues and normal tissues (lung or tongue) was acquired and analyzed from the Oncomine online microarray database. A box-and-whisker plot that represents ITGA2 expression from primary tumors compared to normal specimens in ten datasets from the Oncomine database. The horizontal top and bottom lines of each box represent the 75th and the 25th percentile, respectively. The band in the box is the median value. Horizontal lines above and below the box represent the 90th and the 10th percentile, respectively. The dots above the 90th percentile and below the 10th percentile represent the maximum and minimum values, respectively. From ten lung datasets, integrin α2 (ITGA2) is up-regulated in tumor tissue specimens in comparison to normal tissues. (A, B) The Bhattacharjee Lung dataset compromises 177 specimens, including 17 normal lung specimens, 21 squamous cell carcinoma specimens and 138 lung adenocarcinoma specimens. (C, D) The Garber Lung dataset compromises 59 specimens, including 6 normal lung specimens, 13 squamous cell carcinoma specimens and 40 lung adenocarcinoma specimens. (E) The Hou Lung dataset comprises 92 specimens, including 65 normal lung specimens and 27 squamous cell carcinoma specimens. (F) The Landi Lung dataset compromises 107 specimens, including 49 normal lung specimens and 58 lung adenocarcinoma specimens. (G) The Okayama Lung dataset compromises 246 specimens, including 20 normal lung specimens and 226 lung adenocarcinoma specimens. (H) The Selamat Lung dataset compromises 116 specimens, including 58 normal lung specimens and 58 lung adenocarcinoma specimens. (I) The Stearman Lung dataset compromises 39 specimens, including 19 normal lung specimens and 20 lung adenocarcinoma specimens. (J) The Su Lung dataset compromises 57 specimens, including 30 normal lung specimens and 27 lung adenocarcinoma specimens. (K) The Talbot Lung dataset comprises 62 specimens, including 28 normal lung and tongue specimens and 34 squamous cell carcinoma specimens. (L) The Yamagata Lung dataset comprises 14 specimens, including 3 normal lung specimens and 11 squamous cell carcinoma specimens. ** P < 0.01, *** P < 0.001.